Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TWST 
Twist Bioscience Corp (TWST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TWST (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $48.42
1 Year Target Price $48.42
| 6 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.59% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio - | 1Y Target Price 48.42 |
Price to earnings Ratio - | 1Y Target Price 48.42 | ||
Volume (30-day avg) 12 | Beta 2.37 | 52 Weeks Range 27.12 - 60.90 | Updated Date 06/30/2025 |
52 Weeks Range 27.12 - 60.90 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.98% | Operating Margin (TTM) -44.79% |
Management Effectiveness
Return on Assets (TTM) -15.04% | Return on Equity (TTM) -38.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2025668343 | Price to Sales(TTM) 6.34 |
Enterprise Value 2025668343 | Price to Sales(TTM) 6.34 | ||
Enterprise Value to Revenue 5.83 | Enterprise Value to EBITDA -35.26 | Shares Outstanding 59916100 | Shares Floating 58827465 |
Shares Outstanding 59916100 | Shares Floating 58827465 | ||
Percent Insiders 1.98 | Percent Institutions 114.97 |
Analyst Ratings
Rating 4 | Target Price 48.42 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Twist Bioscience Corp
Company Overview
History and Background
Twist Bioscience Corp was founded in 2013. It has rapidly grown to become a leader in synthetic DNA manufacturing, pioneering the use of silicon-based DNA synthesis. Significant milestones include expanding its product portfolio and forging partnerships with major pharmaceutical and biotech companies.
Core Business Areas
- Synthetic Biology: Provides custom DNA sequences for research and development, including gene synthesis, oligo pools, and variant libraries.
- Next-Generation Sequencing (NGS): Offers tools and services for targeted sequencing, including target enrichment panels and custom solutions.
- Biopharma: Leverages its DNA synthesis platform to discover and develop novel antibody therapeutics and offers antibody optimization services.
Leadership and Structure
Emily Leproust is the CEO and co-founder. The company has a typical corporate structure with functional departments reporting to the executive team and board of directors.
Top Products and Market Share
Key Offerings
- Synthetic Genes: Custom-synthesized DNA sequences used in various research applications. Competitors include IDT (Integrated DNA Technologies) and GenScript. Market share data for Twist Bioscience is difficult to isolate specifically for synthetic genes, but it is a significant player in the overall synthetic biology market.
- Oligo Pools: Libraries of custom DNA oligonucleotides used in diverse applications. Competitors include Agilent and IDT. Market share for oligo pools is also challenging to pinpoint precisely, but Twist is considered a strong contender.
- Target Enrichment Panels: NGS panels used for targeted sequencing applications in cancer research and other areas. Competitors include Illumina and Roche.
Market Dynamics
Industry Overview
The synthetic biology market is experiencing rapid growth, driven by increasing demand for synthetic DNA in research, drug discovery, and industrial biotechnology. The NGS market is also growing rapidly, driven by applications in personalized medicine, diagnostics, and genomics research.
Positioning
Twist Bioscience is positioned as a leading provider of synthetic DNA, leveraging its silicon-based manufacturing platform to offer high-quality, high-throughput products. Its competitive advantages include its technology platform, speed, and scalability.
Total Addressable Market (TAM)
The TAM for synthetic biology and NGS is estimated to be in the billions of dollars. Twist is well-positioned to capture a significant share of this market. The company projects a large TAM and are targeting both growth of existing products and also expanding into new applications and new geographies.
Upturn SWOT Analysis
Strengths
- Proprietary silicon-based DNA synthesis platform
- High-throughput manufacturing capabilities
- Strong customer relationships
- Experienced management team
- Diverse product portfolio
Weaknesses
- Relatively high cost of goods sold (COGS)
- Dependence on a limited number of large customers
- Competition from established players
- Requires significant capital expenditures for manufacturing expansion
Opportunities
- Expanding into new applications of synthetic DNA
- Geographic expansion, particularly in Asia
- Developing new products and services for the biopharma market
- Strategic partnerships and acquisitions
Threats
- Technological advancements by competitors
- Price competition
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- IDT
- DNA2.0
- GenScript
Competitive Landscape
Twist Bioscience offers a competitive advantage in high-throughput DNA synthesis due to its silicon platform, but faces competition from larger and well-established companies with greater financial resources.
Major Acquisitions
Genome Compiler Corporation
- Year: 2016
- Acquisition Price (USD millions): 12
- Strategic Rationale: Acquisition allowed Twist to expand its bioinformatics capabilities.
Growth Trajectory and Initiatives
Historical Growth: Twist Bioscience Corp has experienced significant revenue growth in recent years, driven by increasing demand for its synthetic DNA products and services.
Future Projections: Analysts project continued revenue growth for Twist Bioscience Corp, driven by its expansion into new markets and applications. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, launching new products and services, and forging strategic partnerships with pharmaceutical and biotech companies.
Summary
Twist Bioscience is a leader in synthetic DNA manufacturing with a promising growth trajectory. Its innovative technology and strategic partnerships are driving revenue growth. However, challenges remain in achieving profitability and managing competition. Investors should monitor cash burn and market changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on publicly available information and industry estimates. Financial figures may be rounded.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Twist Bioscience Corp
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-10-31 | Co-Founder, Board Chair & CEO Dr. Emily Marine Leproust Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 923 | Website https://www.twistbioscience.com |
Full time employees 923 | Website https://www.twistbioscience.com | ||
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.